Education
About Us
Working with TipRanks
Follow Us
PureTech Health (PRTC)
NASDAQ:PRTC
Top Page
PureTech Health
(NASDAQ:PRTC)
Rating:60Neutral
Price Target:
$19.00
▲(11.31% Upside)
Positive Factors
Clinical Trial Results
Positive Phase 2b data highlights the potential for LYT-100 to surpass the standard of care, pirfenidone, in treating idiopathic pulmonary fibrosis.
Product Development
The launch of Celea Therapeutics and the advancement of LYT-100 into Phase 3 studies is seen as a strategic move in idiopathic pulmonary fibrosis.
Negative Factors
Program Discontinuations
Discontinuations in the LYT-100 arm were slightly higher compared to those for pirfenidone.
Stock Liquidity
Investor interest in PRTC stock is limited by low liquidity for the ADRs and expectations of asset spin-offs.
PureTech Health (PRTC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$396.20M
Dividend YieldN/A
Average Volume (3M)3.74K
Price to Earnings (P/E)9.6
Beta (1Y)0.63
Revenue Growth1263.40%
EPS GrowthN/A
CountryUS
Employees80
SectorHealthcare
Sector Strength51
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.90
Shares Outstanding24,131,632
10 Day Avg. Volume5,751
30 Day Avg. Volume3,741
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.27
Enterprise Value/Revenue24.69
Enterprise Value/Gross Profit24.69
Enterprise Value/Ebitda2.85
Forecast
1Y Price Target
$19.00Price Target Upside11.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
PureTech Health Business Overview & Revenue Model
Company DescriptionPureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
How the Company Makes MoneyPureTech Health generates revenue through a combination of product sales, licensing agreements, and strategic partnerships. The company develops and commercializes its own pharmaceutical products, which contribute to its revenue through direct sales. Additionally, PureTech Health enters into licensing agreements with other biotechnology and pharmaceutical companies, allowing them to utilize PureTech's proprietary technologies or product candidates, in exchange for upfront payments, milestones, and royalties. The company also engages in collaborations and partnerships with leading academic institutions and industry players, which can provide funding, shared resources, and additional revenue streams. These partnerships often focus on advancing the development of PureTech's pipeline and expanding its reach in the market.
PureTech Health Earnings Call Summary
Earnings Call Date:Aug 28, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Apr 23, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted PureTech's strong cash position and operational efficiency, progress in core founded entities, and strategic financing with promising valuation for Seaport Therapeutics. However, there are challenges with the need for ongoing external financing for core entities and leadership transitions. The overall sentiment is balanced with strong positive aspects but also significant challenges.Q2-2025 Updates
Positive Updates
Strong Cash Position and Operational Efficiency
PureTech ended the half year with just under $320 million in cash, cash equivalents, and short-term investments. Operating expenses reduced from $66.7 million in the same period last year to just under $50 million, demonstrating efficient operations.
Successful Financing and Valuation of Seaport Therapeutics
Seaport Therapeutics, a core founded entity of PureTech, raised over $325 million with a $733 million post-money valuation during its Series B round.
Progress in Core Founded Entities
Significant progress in Celea Therapeutics, Gallop Oncology, and Seaport Therapeutics with promising data in IPF and cancer treatments. Notable FDA designations for LYT-200 in Gallop Oncology.
Significant Potential from Cobenfy Royalties
PureTech holds a 2% royalty on Cobenfy sales above $2 billion annually, with potential milestones projecting around $300 million in value based on analyst forecasts.
Negative Updates
Dependence on External Financing for Core Entities
Celea Therapeutics and Gallop Oncology require external funding to advance their programs, leaving some uncertainty about future financing structures and potential dilution.
Leadership Transition and Interim Management
PureTech is currently under interim leadership with Robert Lyne as Interim CEO, following recent management changes and the departure of the previous Chair.
Company Guidance
During the PureTech Health 2025 Half Year Earnings Webcast, the company provided guidance focusing on three key strategic pillars: developing new treatments with patient-centered urgency, strengthening engagement with U.K. capital markets, and maintaining a disciplined capital allocation approach. PureTech highlighted its promising lead program, deupirfenidone (LYT-100), significant progress in clinical trials, and the potential to deliver long-term value for patients and shareholders. The company also discussed its hub-and-spoke model, exemplified by the success of Karuna Therapeutics, which involved an $18.5 million initial investment leading to a significant financial return. Additionally, PureTech announced plans to appoint up to two new nonexecutive directors to strengthen its board with U.K. capital markets expertise. The interim CEO, Robert Lyne, emphasized their focus on operational discipline and leveraging external capital to fund new entities like Seaport Therapeutics, Gallop Oncology, and Celea Therapeutics, aiming to extend the operational runway well into 2028 with a strong cash position of just under $320 million.PureTech Health Financial Statement Overview
Summary
PureTech Health shows a mixed financial outlook. The balance sheet is strong with low leverage, but income and cash flow statements reveal operational inefficiencies and cash management issues. The transition to positive net income in 2024 is promising, yet sustained profitability remains uncertain.Income Statement
PureTech Health has shown inconsistent revenue growth with a significant increase from 2023 to 2024. However, the company is operating at a loss, with negative EBIT and EBITDA margins indicating operational challenges. Although net profit margin turned positive in 2024, this has been volatile over the years.40
Negative
Balance Sheet
The company's balance sheet shows a strong equity ratio and low debt-to-equity ratio, suggesting good financial stability. However, the decrease in stockholders' equity over recent years could be a concern for long-term sustainability. Return on Equity turned positive in 2024, but this metric has been inconsistent historically.55
Neutral
Cash Flow
Cash flow analysis reveals negative free cash flow, although the company has managed a positive investing cash flow, likely from asset sales or investments. The operating cash flow to net income ratio is negative, suggesting that core operations are not generating sufficient cash.60
Neutral
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.32M | 3.33M | 2.09M | 9.98M | 8.34M |
| Gross Profit | 1.26M | -1.60M | -150.34M | -100.49M | 8.34M |
| EBITDA | 37.38M | -11.63M | -52.19M | -46.95M | 62.69M |
| Net Income | 53.51M | -65.70M | -37.06M | -62.71M | 4.57M |
Balance Sheet | |||||
| Total Assets | 602.63M | 693.97M | 702.65M | 946.01M | 989.99M |
| Cash, Cash Equivalents and Short-Term Investments | 367.31M | 327.14M | 350.10M | 465.71M | 403.88M |
| Total Debt | 22.36M | 25.34M | 46.87M | 52.02M | 76.62M |
| Total Liabilities | 194.70M | 235.74M | 155.06M | 361.86M | 336.45M |
| Stockholders Equity | 414.71M | 464.07M | 542.22M | 593.51M | 669.75M |
Cash Flow | |||||
| Free Cash Flow | -134.38M | -106.16M | -180.97M | -163.94M | -137.25M |
| Operating Cash Flow | -134.37M | -105.92M | -178.79M | -158.27M | -131.83M |
| Investing Cash Flow | 240.89M | 68.99M | -107.22M | 197.38M | 364.48M |
| Financing Cash Flow | -16.96M | 78.14M | -29.83M | 22.73M | 38.87M |
PureTech Health Technical Analysis
Negative
17.07
Price Trends
18.20
Negative
17.87
Negative
18.59
Negative
Market Momentum
-0.10
Positive
42.16
Neutral
4.85
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRTC, the sentiment is Negative. The current price of 17.07 is below the 20-day moving average (MA) of 18.12, below the 50-day MA of 18.20, and below the 200-day MA of 18.59, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 42.16 is Neutral, neither overbought nor oversold. The STOCH value of 4.85 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRTC.
PureTech Health Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $1.08B | 23.38 | 18.17% | ― | 1218.82% | ― | |
60 Neutral | $396.20M | 9.58 | 14.26% | ― | 1263.40% | ― | |
55 Neutral | $797.49M | ― | -73.95% | ― | 2.99% | -49.11% | |
53 Neutral | $509.15M | ― | 3.53% | ― | 158.57% | 96.76% | |
51 Neutral | $7.85B | -0.21 | -41.41% | 2.22% | 22.81% | -2.01% | |
46 Neutral | $357.36M | ― | -57.39% | ― | 27.32% | -1.34% | |
41 Neutral | $399.21M | ― | -52.18% | ― | 187.52% | 26.32% |
* Healthcare Sector Average
Performance Comparison
PRTC
PureTech Health
17.07
-4.63
-21.34%
EYPT
EyePoint Pharmaceuticals
11.57
3.41
41.79%
ZVRA
Zevra Therapeutics
9.07
1.77
24.25%
AUTL
Autolus Therapeutics
1.50
-2.35
-61.04%
STOK
Stoke Therapeutics
19.76
4.73
31.47%
ABSI
AbSci
2.39
-1.60
-40.10%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.